Choosing the Right Probiotic for the Right Child: A Comprehensive, Evidence-Based Review for Pediatric Practice

Background: Probiotics are widely used in pediatrics, yet decisions are confounded by strain heterogeneity, mixed evidence, and variable product quality. Objective: To present a clinician-friendly, strain-specific, indication-first review for use from the newborn period through adolescence, with an India-specific brand–strain mapping. Methods: Narrative synthesis emphasizing ESPGHAN position guidance, Cochrane reviews, major multicenter RCTs in acute gastroenteritis, pediatric data for infantile colic and Helicobacter pylori adjunct therapy, and safety communications from AAP and regulators. Key findings: Antibiotic-associated diarrhea (AAD) prevention has the strongest pediatric evidence with Lactobacillus rhamnosus GG (LGG, ATCC 53103) and Saccharomyces boulardii CNCM I-745. Acute gastroenteritis (AGE) treatment with common lactobacilli showed no benefit in two large NEJM RCTs; regional guidance is cautious. Infantile colic demonstrates consistent benefit with Limosilactobacillus reuteri DSM 17938 (especially in exclusively breast-fed infants). URTI prevention shows modest, strain-heterogeneous effects. Dental/ENT uses (halitosis, gingival indices) have supportive evidence for Streptococcus salivarius K12/M18 as adjuncts to hygiene. Bacillus clausii has pragmatic utility as an acute diarrhea adjunct (India). Preterm/VLBW infants: routine use not recommended by AAP; FDA warns of invasive infection risk. Conclusion: Use an S-D-D-I framework—Strain, Dose, Duration, Indication—prioritizing products with documented strain codes and quality.